Rachel Pullen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachel Pullen has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Amy Couper
Observational and Pragmatic Research Institute, Singapore, Singapore
8 shared publications - David Price
Observational and Pragmatic Research Institute Singapore Singapore
8 shared publications - John R. Hurst
UCL Respiratory, University College London, London, UK
6 shared publications Tonya Winders
Global Allergy & Airways Patient Platform, Vienna, Austria
5 shared publicationsAlexander Evans
Observational and Pragmatic Research Institute, Singapore, Singapore
4 shared publicationsDave Singh
Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 17, 1-19
CONQUEST-ADVANCE: Achieving proDuctiVe implementAtioN of CONQUEST Quality Standards in COPD Care
Background: Integrated COPD management has improved outcomes for patients with diagnosed COPD. The CONQUEST Quality Improvement Program aims to improve the diagnosis and management for patients with potential and diagnosed modifiable high-risk (MHR) COPD, defined as those with a history of exacerbations and opportunities for treatment optimization. Methods: Utilizing the CONQUEST registry and Optimum Patient Care (OPC) Research Database, this observational cohort analysis assessed changes in quality indicator attainment over 12 months among potentially undiagnosed, newly diagnosed and already diagnosed patients with MHR COPD in exposed and matched usual care (UC) general practices. In exposed practices, newly diagnosed and already diagnosed patients were restricted to those receiving OPC-led CONQUEST clinics. Outcomes were compared using difference-in-difference generalized linear models with overlap propensity weighting. Findings: From 168 UK practices, we identified 113,574 potentially undiagnosed (59,706 exposed, 53,868 UC), 2787 newly diagnosed (1448 exposed of which 252 attended OPC clinics, 1339 UC) and 38,054 already diagnosed (21,670 exposed of which 392 attended OPC clinics, 16,384 UC). Potentially undiagnosed patients in exposed practices were more likely to subsequently receive a spirometry-confirmed COPD diagnosis (1.0% vs 0.6%; adjusted ratios-of-risk-ratios [ARRR]:1.55, 95% CI: 1.19– 2.01) compared to UC. Initiation or step-up to guideline-appropriate inhaled therapy was more likely among OPC-supported patients in exposed practices for newly diagnosed (96.4% vs 55.7%; ARRR: 1.71, 95% CI: 1.41– 2.06) and already diagnosed (91.6% vs 39.8%; ARRR: 1.94, 95% CI: 1.77– 2.1212) versus unsupported UC. Interpretation: CONQUEST is associated with measurable improvements in quality indicator attainment aligned with guideline-recommended identification and management of COPD, including higher rates of spirometry-confirmed COPD diagnosis and treatment optimization. Future randomized trials will evaluate if this translates into improved outcomes including reduced exacerbations and hospitalizations.
- 1 October 2026
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 17, 1-19
Open AccessCONQUEST-ADVANCE: Achieving proDuctiVe implementAtioN of CONQUEST Quality Standards in COPD Care
Background: Integrated COPD management has improved outcomes for patients with diagnosed COPD. The CONQUEST Quality Improvement Program aims to improve the diagnosis and management for patients with potential and diagnosed modifiable high-risk (MHR) COPD, defined as those with a history of exacerbations and opportunities for treatment optimization. Methods: Utilizing the CONQUEST registry and Optimum Patient Care (OPC) Research Database, this observational cohort analysis assessed changes in quality indicator attainment over 12 months among potentially undiagnosed, newly diagnosed and already diagnosed patients with MHR COPD in exposed and matched usual care (UC) general practices. In exposed practices, newly diagnosed and already diagnosed patients were restricted to those receiving OPC-led CONQUEST clinics. Outcomes were compared using difference-in-difference generalized linear models with overlap propensity weighting. Findings: From 168 UK practices, we identified 113,574 potentially undiagnosed (59,706 exposed, 53,868 UC), 2787 newly diagnosed (1448 exposed of which 252 attended OPC clinics, 1339 UC) and 38,054 already diagnosed (21,670 exposed of which 392 attended OPC clinics, 16,384 UC). Potentially undiagnosed patients in exposed practices were more likely to subsequently receive a spirometry-confirmed COPD diagnosis (1.0% vs 0.6%; adjusted ratios-of-risk-ratios [ARRR]:1.55, 95% CI: 1.19– 2.01) compared to UC. Initiation or step-up to guideline-appropriate inhaled therapy was more likely among OPC-supported patients in exposed practices for newly diagnosed (96.4% vs 55.7%; ARRR: 1.71, 95% CI: 1.41– 2.06) and already diagnosed (91.6% vs 39.8%; ARRR: 1.94, 95% CI: 1.77– 2.1212) versus unsupported UC. Interpretation: CONQUEST is associated with measurable improvements in quality indicator attainment aligned with guideline-recommended identification and management of COPD, including higher rates of spirometry-confirmed COPD diagnosis and treatment optimization. Future randomized trials will evaluate if this translates into improved outcomes including reduced exacerbations and hospitalizations.
- Open Access
- 22 September 2026
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 27, e106
Implementing quality improvement for patients with high-risk chronic disease: lessons from the CONQUEST UK COPD programme
Large-scale quality improvement programmes (QIPs) have diverse factors that may influence their success and can undergo rapid changes throughout their lifecycle. The COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) programme has recently been implemented in primary care practices in the UK. The CONQUEST programme aims to identify patients with already diagnosed and undiagnosed COPD at high risk of COPD-related adverse outcomes and optimize their management. CONQUEST has been successful in identifying COPD patients who may represent an outsized opportunity to improve patient outcomes and healthcare utilization, whilst focusing on relatively few patients per primary care practice. This paper reviews the steps involved in implementing CONQUEST in the UK, focussing on the challenges encountered, the solutions used to overcome these challenges barriers, and the lessons learned for the implementation of QIPs more widely. Key lessons from this process include that QIPs need to be designed with the flexibility to adapt to multiple and different local contexts, that early monitoring of data across the lifecycle of a QIP allows efficient detection of issues and troubleshooting, and that planning for allocation of limited resources to a QIP is essential for real-world implementation. The problems and solutions described here are applicable to QIPs in a wide variety of high-risk diseases and different healthcare settings.
- 22 September 2026
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 27, e106
Open AccessImplementing quality improvement for patients with high-risk chronic disease: lessons from the CONQUEST UK COPD programme
Large-scale quality improvement programmes (QIPs) have diverse factors that may influence their success and can undergo rapid changes throughout their lifecycle. The COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) programme has recently been implemented in primary care practices in the UK. The CONQUEST programme aims to identify patients with already diagnosed and undiagnosed COPD at high risk of COPD-related adverse outcomes and optimize their management. CONQUEST has been successful in identifying COPD patients who may represent an outsized opportunity to improve patient outcomes and healthcare utilization, whilst focusing on relatively few patients per primary care practice. This paper reviews the steps involved in implementing CONQUEST in the UK, focussing on the challenges encountered, the solutions used to overcome these challenges barriers, and the lessons learned for the implementation of QIPs more widely. Key lessons from this process include that QIPs need to be designed with the flexibility to adapt to multiple and different local contexts, that early monitoring of data across the lifecycle of a QIP allows efficient detection of issues and troubleshooting, and that planning for allocation of limited resources to a QIP is essential for real-world implementation. The problems and solutions described here are applicable to QIPs in a wide variety of high-risk diseases and different healthcare settings.
- Open Access
- 11 June 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Prevalence of type 2 multimorbidities in COPD compared to asthma and relationship to blood eosinophilic counts
Background: Type 2 (T2) inflammation is increasingly recognized in chronic obstructive pulmonary disease (COPD), though its immunopathological profile may differ from asthma. T2 inflammatory diseases often coexist, but their prevalence in COPD patients without asthma remains underexplored. Objective: This study investigated the prevalence of T2 inflammatory multimorbidities in individuals with COPD (without asthma) and compared it with those in people with asthma. It also examined the relationship between these multimorbidities and blood eosinophil counts (BEC). Methods: Using data from the Optimum Patient Care Research Database (OPCRD), we identified patients with COPD or asthma and assessed lifetime and adjusted prevalence of T2 comorbidities including allergic rhinitis, atopic dermatitis/eczema, nasal polyps, chronic rhinitis with or without polyps, eosinophilic oesophagitis, and ulcerative colitis. Prevalence was stratified by BEC and adjusted for demographic and clinical variables. Results: Among 122 509 COPD and 1 154 094 asthma patients, T2 multimorbidities were present in both groups but significantly less common in COPD. Allergic rhinitis and nasal polyps were notably less prevalent in COPD, even at higher BEC levels. Prevalence of multimorbidities increased with BEC in both groups, with stronger associations observed for nasal polyps and UC. Eosinophilic oesophagitis was rare across both cohorts. Conclusion: T2 multimorbidities are present in COPD and their prevalence increases with BEC, though they are generally less prevalent than in asthma, suggesting distinct immunopathological.
- 11 June 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Open AccessPrevalence of type 2 multimorbidities in COPD compared to asthma and relationship to blood eosinophilic counts
Background: Type 2 (T2) inflammation is increasingly recognized in chronic obstructive pulmonary disease (COPD), though its immunopathological profile may differ from asthma. T2 inflammatory diseases often coexist, but their prevalence in COPD patients without asthma remains underexplored. Objective: This study investigated the prevalence of T2 inflammatory multimorbidities in individuals with COPD (without asthma) and compared it with those in people with asthma. It also examined the relationship between these multimorbidities and blood eosinophil counts (BEC). Methods: Using data from the Optimum Patient Care Research Database (OPCRD), we identified patients with COPD or asthma and assessed lifetime and adjusted prevalence of T2 comorbidities including allergic rhinitis, atopic dermatitis/eczema, nasal polyps, chronic rhinitis with or without polyps, eosinophilic oesophagitis, and ulcerative colitis. Prevalence was stratified by BEC and adjusted for demographic and clinical variables. Results: Among 122 509 COPD and 1 154 094 asthma patients, T2 multimorbidities were present in both groups but significantly less common in COPD. Allergic rhinitis and nasal polyps were notably less prevalent in COPD, even at higher BEC levels. Prevalence of multimorbidities increased with BEC in both groups, with stronger associations observed for nasal polyps and UC. Eosinophilic oesophagitis was rare across both cohorts. Conclusion: T2 multimorbidities are present in COPD and their prevalence increases with BEC, though they are generally less prevalent than in asthma, suggesting distinct immunopathological.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 17, 1-20
Development and Internal Validation of a Prediction Model for Major Cardiovascular and Respiratory Events in Chronic Obstructive Pulmonary Disease: Nationwide Primary Care Electronic Medical Records Cohort Study
Background: Cardiovascular diseases are prevalent in individuals with chronic obstructive pulmonary disease (COPD), but current cardiovascular risk assessment models are not optimised for COPD. We aimed to develop a prediction model for the 10-year risk of major adverse cardiovascular and respiratory events (MACRE) in patients with COPD. Methods: We used nationwide primary care electronic health records from individuals with COPD, aged ≥ 40 years in 2011 without prior myocardial infarction in the UK Optimum Patient Care Research Database. Practices were randomly divided at the practice level into derivation (80%) and validation (20%) datasets. The primary composite outcome (MACRE) consisted of myocardial infarction, coronary revascularization, heart failure, severe COPD exacerbation, and all-cause mortality. Multivariable Cox regression was used to derive the model using the derivation dataset, with the least absolute shrinkage and selection operator used for variable selection and shrinkage. Performance was evaluated using the validation dataset over prediction horizons of five and 10 years. Results: Among the 122,077 patients included (98,959 in the derivation set; whole cohort: 47.9% women and mean age 69.3 (SD 11.2) years), cardiometabolic risk factors were prevalent, and most had moderate (53.4%) or severe (24.7%) COPD. Over a median follow-up of 10.5 [interquartile range: 4.2– 12.4] years, MACRE occurred in 50.2% of the validation set. Sixty-one predictor variables constituted the model, which demonstrated good-to-excellent discrimination and satisfactory calibration across prediction horizons (AUROC 0.78 at five years and 0.82 at 10 years, Brier score of 0.18 at five years and 0.16 at 10 years) in the validation set. Conclusion: A model derived using electronic medical records predicts MACRE in COPD with high discrimination and satisfactory calibration across medium and longer-term prediction horizons. Its utility to inform trial enrolment and clinical decisions requires further study. Plain Language Summary: In this study, we used medical records from the United Kingdom (UK) and selected 122,077 patients with a long-term lung condition called chronic obstructive pulmonary disease (COPD) to find the factors which make them more likely to have a heart or lung flare-up in the following years. We found that:Half of the selected patients went on to have a major heart- or lung-related event during the study period, which spanned at least 10.5 years for half of the patients. Sixty-one factors, selected from data routinely collected during clinical consultations, were found to predict the chance of a major heart or lung-related event happening over both the medium (5-year) and long (10 year) term.Future work should allow healthcare professionals to identify patients under their care who are most likely to have heart or lung flare-ups in the next 5 to 10 years, so that they can act earlier and be proactive in lowering the chance of such events happening.
- 1 March 2026
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 17, 1-20
Open AccessDevelopment and Internal Validation of a Prediction Model for Major Cardiovascular and Respiratory Events in Chronic Obstructive Pulmonary Disease: Nationwide Primary Care Electronic Medical Records Cohort Study
Background: Cardiovascular diseases are prevalent in individuals with chronic obstructive pulmonary disease (COPD), but current cardiovascular risk assessment models are not optimised for COPD. We aimed to develop a prediction model for the 10-year risk of major adverse cardiovascular and respiratory events (MACRE) in patients with COPD. Methods: We used nationwide primary care electronic health records from individuals with COPD, aged ≥ 40 years in 2011 without prior myocardial infarction in the UK Optimum Patient Care Research Database. Practices were randomly divided at the practice level into derivation (80%) and validation (20%) datasets. The primary composite outcome (MACRE) consisted of myocardial infarction, coronary revascularization, heart failure, severe COPD exacerbation, and all-cause mortality. Multivariable Cox regression was used to derive the model using the derivation dataset, with the least absolute shrinkage and selection operator used for variable selection and shrinkage. Performance was evaluated using the validation dataset over prediction horizons of five and 10 years. Results: Among the 122,077 patients included (98,959 in the derivation set; whole cohort: 47.9% women and mean age 69.3 (SD 11.2) years), cardiometabolic risk factors were prevalent, and most had moderate (53.4%) or severe (24.7%) COPD. Over a median follow-up of 10.5 [interquartile range: 4.2– 12.4] years, MACRE occurred in 50.2% of the validation set. Sixty-one predictor variables constituted the model, which demonstrated good-to-excellent discrimination and satisfactory calibration across prediction horizons (AUROC 0.78 at five years and 0.82 at 10 years, Brier score of 0.18 at five years and 0.16 at 10 years) in the validation set. Conclusion: A model derived using electronic medical records predicts MACRE in COPD with high discrimination and satisfactory calibration across medium and longer-term prediction horizons. Its utility to inform trial enrolment and clinical decisions requires further study. Plain Language Summary: In this study, we used medical records from the United Kingdom (UK) and selected 122,077 patients with a long-term lung condition called chronic obstructive pulmonary disease (COPD) to find the factors which make them more likely to have a heart or lung flare-up in the following years. We found that:Half of the selected patients went on to have a major heart- or lung-related event during the study period, which spanned at least 10.5 years for half of the patients. Sixty-one factors, selected from data routinely collected during clinical consultations, were found to predict the chance of a major heart or lung-related event happening over both the medium (5-year) and long (10 year) term.Future work should allow healthcare professionals to identify patients under their care who are most likely to have heart or lung flare-ups in the next 5 to 10 years, so that they can act earlier and be proactive in lowering the chance of such events happening.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 16, 243-251
Derivation and Definitions of Clinical Study Variables for Multiple Long Term Conditions in Patients with Chronic Obstructive Pulmonary Disease: Protocol for a Modified Delphi Methods and Consensus Study on Behalf of the International Cardiovascular and Respiratory Alliance
Standardized variables and their definitions are essential for robust delivery and reporting of clinical studies and quality improvement in chronic obstructive pulmonary disease (COPD). This protocol describes the rationale and methodology for the derivation and definition of clinical study variables for patients with multimorbidity or at high risk of multimorbidity in COPD. We will follow a four-step process. This will include the formation of an Executive Committee, a Steering Committee and an International Consensus Group. We will conduct a systematic review of the literature from which potential clinical study variables will be extracted and their definitions proposed. Using a modified Delphi process, the Steering Committee will select candidate clinical study variables and as necessary refine their definitions. All three groups will then vote and give feedback on the candidate clinical study variables in a modified Delphi process (with rounds until consensus is achieved) to reach a final suite of internationally agreed hierarchically classified clinical study variables. It is anticipated that the results will be published in a peer-reviewed journal and presented in a variety of forums. Ethical approval was not required for this study.
- 1 December 2025
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 16, 243-251
Open AccessDerivation and Definitions of Clinical Study Variables for Multiple Long Term Conditions in Patients with Chronic Obstructive Pulmonary Disease: Protocol for a Modified Delphi Methods and Consensus Study on Behalf of the International Cardiovascular and Respiratory Alliance
Standardized variables and their definitions are essential for robust delivery and reporting of clinical studies and quality improvement in chronic obstructive pulmonary disease (COPD). This protocol describes the rationale and methodology for the derivation and definition of clinical study variables for patients with multimorbidity or at high risk of multimorbidity in COPD. We will follow a four-step process. This will include the formation of an Executive Committee, a Steering Committee and an International Consensus Group. We will conduct a systematic review of the literature from which potential clinical study variables will be extracted and their definitions proposed. Using a modified Delphi process, the Steering Committee will select candidate clinical study variables and as necessary refine their definitions. All three groups will then vote and give feedback on the candidate clinical study variables in a modified Delphi process (with rounds until consensus is achieved) to reach a final suite of internationally agreed hierarchically classified clinical study variables. It is anticipated that the results will be published in a peer-reviewed journal and presented in a variety of forums. Ethical approval was not required for this study.
- Open Access
- 23 June 2025
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 26, e50
Practical strategies for achieving system change in the US: lessons and insights from the CONQUEST quality improvement programme
Background: Quality improvement programmes (QIPs) are designed to enhance patient outcomes by systematically introducing evidence-based clinical practices. The CONQUEST QIP focuses on improving the identification and management of patients with COPD in primary care. The process of developing CONQUEST, recruiting, preparing systems for participation, and implementing the QIP across three integrated healthcare systems (IHSs) is examined to identify and share lessons learned. Approach and development: This review is organized into three stages: 1) development, 2) preparing IHSs for implementation, and 3) implementation. In each stage, key steps are described with the lessons learned and how they can inform others interested in developing QIPs designed to improve the care of patients with chronic conditions in primary care. Stage 1 was establishing and working with steering committees to develop the QIP Quality Standards, define the target patient population, assess current management practices, and create a global operational protocol. Additionally, potential IHSs were assessed for feasibility of QIP integration into primary care practices. Factors assessed included a review of technological infrastructure, QI experience, and capacity for effective implementation. Stage 2 was preparation for implementation. Key was enlisting clinical champions to advocate for the QIP, secure participation in primary care, and establish effective communication channels. Preparation for implementation required obtaining IHS approvals, ensuring Health Insurance Portability and Accountability Act compliance, and devising operational strategies for patient outreach and clinical decision support delivery. Stage 3 was developing three IHS implementation models. With insight into the local context from local clinicians, implementation models were adapted to work with the resources and capacity of the IHSs while ensuring the delivery of essential elements of the programme. Conclusion: Developing and launching a QIP programme across primary care practices requires extensive groundwork, preparation, and committed local champions to assist in building an adaptable environment that encourages open communication and is receptive to feedback.
- 23 June 2025
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 26, e50
Open AccessPractical strategies for achieving system change in the US: lessons and insights from the CONQUEST quality improvement programme
Background: Quality improvement programmes (QIPs) are designed to enhance patient outcomes by systematically introducing evidence-based clinical practices. The CONQUEST QIP focuses on improving the identification and management of patients with COPD in primary care. The process of developing CONQUEST, recruiting, preparing systems for participation, and implementing the QIP across three integrated healthcare systems (IHSs) is examined to identify and share lessons learned. Approach and development: This review is organized into three stages: 1) development, 2) preparing IHSs for implementation, and 3) implementation. In each stage, key steps are described with the lessons learned and how they can inform others interested in developing QIPs designed to improve the care of patients with chronic conditions in primary care. Stage 1 was establishing and working with steering committees to develop the QIP Quality Standards, define the target patient population, assess current management practices, and create a global operational protocol. Additionally, potential IHSs were assessed for feasibility of QIP integration into primary care practices. Factors assessed included a review of technological infrastructure, QI experience, and capacity for effective implementation. Stage 2 was preparation for implementation. Key was enlisting clinical champions to advocate for the QIP, secure participation in primary care, and establish effective communication channels. Preparation for implementation required obtaining IHS approvals, ensuring Health Insurance Portability and Accountability Act compliance, and devising operational strategies for patient outreach and clinical decision support delivery. Stage 3 was developing three IHS implementation models. With insight into the local context from local clinicians, implementation models were adapted to work with the resources and capacity of the IHSs while ensuring the delivery of essential elements of the programme. Conclusion: Developing and launching a QIP programme across primary care practices requires extensive groundwork, preparation, and committed local champions to assist in building an adaptable environment that encourages open communication and is receptive to feedback.
- Open Access
- 21 April 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 29, 100619
Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study
- 21 April 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 29, 100619
Open AccessIdentification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study
- Open Access
- 1 February 2022
- Published by Taylor & Francis in Patient Related Outcome Measures
- Vol. ume 13, 53-68
CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
The COllaboration on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) aims to improve the quality of COPD care in primary care. The CONQUEST target population includes patients diagnosed with COPD, and those undiagnosed but with COPD-like exacerbations, who are at high but modifiable risk of COPD exacerbations, increased morbidity, and mortality. Timely diagnosis and optimized management to reduce these risks is vital. There is a need for a quality improvement program (QIP) that enables long-term improvement of patient clinical outcomes via integration of the program into routine clinical care. Core to the CONQUEST program is the adoption of four specifically designed, globally applicable, and expert-agreed quality standards (QS) for modifiable high-risk COPD patients. Translation of the QS into clinical practice, and implementation of the QIP, is guided by the CONQUEST global operational protocol provided to sites meeting the minimum healthcare system requirements. Initial analyses of current practices are conducted to generate baseline assessments of need within healthcare systems and sites looking to implement the QIP. Implementation is supported by the provision of CONQUEST resources and tools, such as clinical decision support, that promote prompt identification and treatment of patients. Utilization of electronic medical record (EMR) and patient-reported data are integral components of the QIP. Regular, automated collection and analysis of data, combined with a cyclical review of the implementation process, will be conducted for long-term, continuous improvement and health impact evaluation. The CONQUEST QIP will be an important resource in the identification and management of patients with modifiable high-risk COPD. Embedding the CONQUEST QS into routine clinical practice with regular evaluation and feedback will result in long-term quality of care improvement.
- 1 February 2022
- Published by Taylor & Francis in Patient Related Outcome Measures
- Vol. ume 13, 53-68
Open AccessCONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
The COllaboration on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) aims to improve the quality of COPD care in primary care. The CONQUEST target population includes patients diagnosed with COPD, and those undiagnosed but with COPD-like exacerbations, who are at high but modifiable risk of COPD exacerbations, increased morbidity, and mortality. Timely diagnosis and optimized management to reduce these risks is vital. There is a need for a quality improvement program (QIP) that enables long-term improvement of patient clinical outcomes via integration of the program into routine clinical care. Core to the CONQUEST program is the adoption of four specifically designed, globally applicable, and expert-agreed quality standards (QS) for modifiable high-risk COPD patients. Translation of the QS into clinical practice, and implementation of the QIP, is guided by the CONQUEST global operational protocol provided to sites meeting the minimum healthcare system requirements. Initial analyses of current practices are conducted to generate baseline assessments of need within healthcare systems and sites looking to implement the QIP. Implementation is supported by the provision of CONQUEST resources and tools, such as clinical decision support, that promote prompt identification and treatment of patients. Utilization of electronic medical record (EMR) and patient-reported data are integral components of the QIP. Regular, automated collection and analysis of data, combined with a cyclical review of the implementation process, will be conducted for long-term, continuous improvement and health impact evaluation. The CONQUEST QIP will be an important resource in the identification and management of patients with modifiable high-risk COPD. Embedding the CONQUEST QS into routine clinical practice with regular evaluation and feedback will result in long-term quality of care improvement.
- Open Access
- 1 August 2021
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 2301-2322
CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
Background: Chronic obstructive pulmonary disease (COPD) are managed predominantly in primary care. However, key opportunities to optimize treatment are often not realized due to unrecognized disease and delayed implementation of appropriate interventions for both diagnosed and undiagnosed individuals. The COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) is the first-of-its-kind, collaborative, interventional COPD registry. It comprises an integrated quality improvement program focusing on patients (diagnosed and undiagnosed) at a modifiable and higher risk of COPD exacerbations. The first step in CONQUEST was the development of quality standards (QS). The QS will be imbedded in routine primary and secondary care, and are designed to drive patient-centered, targeted, risk-based assessment and management optimization. Our aim is to provide an overview of the CONQUEST QS, including how they were developed, as well as the rationale for, and evidence to support, their inclusion in healthcare systems. Methods: The QS were developed (between November 2019 and December 2020) by the CONQUEST Global Steering Committee, including 11 internationally recognized experts with a specialty and research focus in COPD. The process included an extensive literature review, generation of QS draft wording, three iterative rounds of review, and consensus. Results: Four QS were developed: 1) identification of COPD target population, 2) assessment of disease and quantification of future risk, 3) non-pharmacological and pharmacological intervention, and 4) appropriate follow-up. Each QS is followed by a rationale statement and a summary of current guidelines and research evidence relating to the standard and its components. Conclusion: The CONQUEST QS represent an important step in our aim to improve care for patients with COPD in primary and secondary care. They will help to transform the patient journey, by encouraging early intervention to identify, assess, optimally manage and followup COPD patients with modifiable high risk of future exacerbations.
- 1 August 2021
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 2301-2322
Open AccessCONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
Background: Chronic obstructive pulmonary disease (COPD) are managed predominantly in primary care. However, key opportunities to optimize treatment are often not realized due to unrecognized disease and delayed implementation of appropriate interventions for both diagnosed and undiagnosed individuals. The COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) is the first-of-its-kind, collaborative, interventional COPD registry. It comprises an integrated quality improvement program focusing on patients (diagnosed and undiagnosed) at a modifiable and higher risk of COPD exacerbations. The first step in CONQUEST was the development of quality standards (QS). The QS will be imbedded in routine primary and secondary care, and are designed to drive patient-centered, targeted, risk-based assessment and management optimization. Our aim is to provide an overview of the CONQUEST QS, including how they were developed, as well as the rationale for, and evidence to support, their inclusion in healthcare systems. Methods: The QS were developed (between November 2019 and December 2020) by the CONQUEST Global Steering Committee, including 11 internationally recognized experts with a specialty and research focus in COPD. The process included an extensive literature review, generation of QS draft wording, three iterative rounds of review, and consensus. Results: Four QS were developed: 1) identification of COPD target population, 2) assessment of disease and quantification of future risk, 3) non-pharmacological and pharmacological intervention, and 4) appropriate follow-up. Each QS is followed by a rationale statement and a summary of current guidelines and research evidence relating to the standard and its components. Conclusion: The CONQUEST QS represent an important step in our aim to improve care for patients with COPD in primary and secondary care. They will help to transform the patient journey, by encouraging early intervention to identify, assess, optimally manage and followup COPD patients with modifiable high risk of future exacerbations.